Completed PHASE1 INTERVENTIONAL 2-arm NCT00770978

Open Label Study of Ceftobiprole to Evaluate Pharmacokinetics in Adults Hospitalized in the ICU

Open-Label, Parallel Group, Multiple-dose Study of Ceftobiprole to Evaluate the Plasma Pharmacokinetics in Adults in Intensive Care Units

Sponsor: Basilea Pharmaceutica

Conditions ICU

Interventions ceftobiprole q12h ceftobiprole q8h

Updated 7 times since 2017 Last updated: Jul 27, 2012 Started: Nov 30, 2008 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00770978, this PHASE1 trial focuses on ICU and remains completed. Sponsored by Basilea Pharmaceutica, it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Basilea Pharmaceutica

Data source: Basilea Pharmaceutica

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Barcelona, Spain , Beech Grove, United States , Birmingham, United States , Chicago, United States , Edegem, Belgium , Greenfield Park, Canada , Gwangju, South Korea , Incheon, South Korea , Jerusalem, Israel and 3 more locations